Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 13-16,20, 2015.
Artigo em Chinês | WPRIM | ID: wpr-603135

RESUMO

Objective To explore an optimal method of producing STZ-induced type 1 diabetic KM mice model by investigating the molded rate of single high dose and multiple low dose of STZ injection.Methods Sixty KM mice were randomly divided into 4 groups(n=15), two control groups and two model groups.In the two control groups, one was blank control and the other was negative control.Mice in the blank control group treated with no injection, but mice in the negative control group were treated with injection of citric acid salt buffer.For the two model groups, one was single high-dose group, 150 mg/kg STZ was injected only once.The other was multiple low-dose group, 50 mg/kg STZ was injected for 5 consecutive days.After the last injection, daily food and water intake were tested, blood glucose level and body weight were examined once a week for 4 consecutive weeks. Results Mice in the two model groups showed typical features of diabetes.The blood glucose levels in the two model groups were significantly higher than in the two control groups ( P <0.05 ) .For the two model groups, the molded rate of 150 mg/kg and 50 mg/kg group were 60% and 53.33%respectively at 1st week, but at the 4th week, they were 60% and 80% respectively.The mortality of these two groups at the 4th week was 33.33% and 20% respectively.Moreover, the blood glucose level in multiple low-dose group increased stably from the 2nd week to the 4th week.Conclusion The multiple low-dose STZ injection (50 mg/kg for 5 consecutive days) is an optimal method for producing KM mice model of type 1 diabetes mellitus.

2.
Journal of the Korean Pediatric Society ; : 1582-1587, 1997.
Artigo em Coreano | WPRIM | ID: wpr-123838

RESUMO

PURPOSE: Since the effect of intravenous immunoglobulin (IVIG) therapy in Kawasaki disease was reported in 1984, the combined therapy of IVIG & oral aspirin has been popular. In early period, the protocol of 400mg/kg/day for 3-5 days of IVIG had been used, but rescently, the protocol of 2g/kg/day single dose has been preferred. So authers performed a clinical study to compare th efficacies & side effects between 400mg/ kg/day for 5 days & 2g/kg/day single dose of IVIG plus oral aspirin (100mg/kg/ day). METHODS: Seventy five patients who admitted to Eulji medical college hospital from January 1990 to July 1996 were evaluated retrospectively. Twenty nine patients (Group A) were treated with 400mg/kg/day for 5 days of IVIG plus aspirin (100mg/kg/day) and 46 patients (Group B) were treated with 2g/kg/day single dose of IVIG plus oral aspirin (100mg/kg/day). RESULTS: 1) The duration of fever after treatment was not significant difference between two groups (Group A, 25.5+/-30.3 days : Group B, 29.7+/-44.5 days P=0.7440) 2) The total admission days were significant difference between two groups (Group A, 9.9+/-0.4; Group B, 8.2+/-3.0, P=0.0308). 3) The incidence of side effects was not significant difference between two groups (Group A, 62%; Group B, 80%, P=0799). 4) The attack rate of coronary artery involvement was not significant difference between two groups (Group A, 34.5%; Group B, 26%, P=0.1198) 5) The case of re-treatment of IVIG due to relapse was not in Group A, but 5 in Group B (P=0.0661). 6) The mean platelet counts at admission were not difference between two groups (Group A, 434.4+/-17.2x103/mm3; Group B, 374.0+/-13.3x103/mm3, P=0.1449), but on the 7th hospital day, platelet counts were significant differnece between two groups (Group A, 531.9+/-16.5x103/mm3; Group B, 419.8+/-19.0x103/mm3, P=0.0066). 7) There was no significant difference in laboratory findings on admission and in the rate of coronary artery involvement between recurrent and non-recurrent cases of Group B. Conculusions : We conculuded that the protocol of 2mg/kg/day single dose of IVIG in Kawasaki disease may be have some benefits of shorter admission days and less coronary artery involvement, but the incidence of side effects and relapse rate might be less in the protocol of 400mg/kg/day of IVIG for 5 days.


Assuntos
Humanos , Aspirina , Vasos Coronários , Febre , Imunoglobulinas , Imunoglobulinas Intravenosas , Incidência , Síndrome de Linfonodos Mucocutâneos , Contagem de Plaquetas , Recidiva , Estudos Retrospectivos
3.
Journal of the Korean Pediatric Society ; : 342-348, 1992.
Artigo em Coreano | WPRIM | ID: wpr-165715

RESUMO

No abstract available.


Assuntos
Síndrome de Linfonodos Mucocutâneos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA